AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23640923 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat (HF) meals given to NW and OB women
Number of subjects: 0
Study 23640923 — intervention group
Group type: EXPERIMENTAL
Intervention: Lcn2 treatment in adipocytes
Number of subjects: 0
Study 21209304 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional treatment plus religious and spiritual assessment
Number of subjects: 78
Study 21209304 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 78
Study 20183688 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided psychotherapy (CP)
Number of subjects: 23
Study 17225971 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-Lab sessions
Number of subjects: 12
Study 17225971 — intervention group
Group type: EXPERIMENTAL
Intervention: P-Lab sessions
Number of subjects: 12
Study 17225971 — intervention group
Group type: COMPARATOR
Intervention: VR-Lab
Number of subjects: 12
Study 15569835 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg and losartan 100 mg
Number of subjects: 47
Study 15569835 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 47
Study 15569835 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg
Number of subjects: 47
Study 11224005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 113
Study 11224005 — intervention group
Group type: COMPARATOR
Intervention: Fasting glucose, fasting insulin, insulin 120 min after glucose ingestion
Number of subjects: 113
Study 9846679 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-agonist down regulation for 15-24 days (Group A)
Number of subjects: 86
Study 9846679 — intervention group
Group type: COMPARATOR
Intervention: GnRH-agonist down regulation for 25-40 days (Group B)
Number of subjects: 86
Study 7855098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea consumption (8 g of instant tea) during supplementation periods in Study A
Number of subjects: 18
Study 7855098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea consumption (8 g of instant tea) during supplementation periods in Study B
Number of subjects: 18
Study 7855098 — intervention group
Group type: COMPARATOR
Intervention: No tea dietary treatments in Study A
Number of subjects: 18
Study 7855098 — intervention group
Group type: COMPARATOR
Intervention: No tea dietary treatments in Study B
Number of subjects: 18
Study 2239725 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose labetalol
Number of subjects: 10
Study 2239725 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose labetalol
Number of subjects: 10
Study 2239725 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 10
Study 2239725 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin with half-dose labetalol
Number of subjects: 10
Study 2239725 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin with full-dose labetalol
Number of subjects: 10
Study 2239725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 417581 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g of iopronic acid
Number of subjects: 180
Study 417581 — intervention group
Group type: COMPARATOR
Intervention: 3.0 g of iopanoic acid
Number of subjects: 180
Study 31152584 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerated conditions with high nutrient levels
Number of subjects: 0
Study 31152584 — intervention group
Group type: COMPARATOR
Intervention: Stagnant conditions with high nutrient levels
Number of subjects: 0
Study 31152584 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerated conditions with low nutrient levels
Number of subjects: 0
Study 31152584 — intervention group
Group type: COMPARATOR
Intervention: Stagnant conditions with low nutrient levels
Number of subjects: 0
Study 31152584 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerated conditions
Number of subjects: 0
Study 31152584 — intervention group
Group type: COMPARATOR
Intervention: Stagnant conditions
Number of subjects: 0
Study 28667579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 3000 mg plus wheat germ oil (WGO) 300 mg
Number of subjects: 46
Study 28667579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26126970 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel (WP) for 12 treatments
Number of subjects: 50
Study 26126970 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (E) every 3 weeks for 4 cycles followed by doxorubicin and cyclophosphamide (AC) every 3 weeks for 4 cycles
Number of subjects: 50
Study 23444963 — intervention group
Group type: EXPERIMENTAL
Intervention: High kimchi intake (210 g/day)
Number of subjects: 100
Study 23444963 — intervention group
Group type: COMPARATOR
Intervention: Low kimchi intake (15 g/day)
Number of subjects: 100
Study 23444963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (low and high kimchi intake)
Number of subjects: 100
Study 21138357 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) combined with bovine-derived xenograft (BDX)
Number of subjects: 20
Study 21138357 — intervention group
Group type: COMPARATOR
Intervention: Platelet-poor plasma (PPP) combined with bovine-derived xenograft (BDX)
Number of subjects: 20
Study 19173710 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine-glutamine infusion at a rate of 0.025 g/(kg body weight x hour) for 10 hours
Number of subjects: 8
Study 19173710 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion for 10 hours
Number of subjects: 8
Study 19173710 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine-glutamine infusion
Number of subjects: 8
Study 19173710 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 17300878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch 21 mg/day
Number of subjects: 42
Study 17300878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch 42 mg/day
Number of subjects: 42
Study 17300878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch 63 mg/day
Number of subjects: 42
Study 17300878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 14996516 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine hydrochloride 0.05% ophthalmic solution
Number of subjects: 67
Study 14996516 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 67
Study 11817197 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling interventions (two types)
Number of subjects: 0
Study 11817197 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling
Number of subjects: 0
Study 11817197 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 0
Study 9006598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated daily phone calls program
Number of subjects: 0
Study 8252685 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 25
Study 8252685 — intervention group
Group type: EXPERIMENTAL
Intervention: Diatrizoate
Number of subjects: 25
Study 8252685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 25
Study 8252685 — intervention group
Group type: COMPARATOR
Intervention: Contrast agents (general)
Number of subjects: 25
Study 8252685 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 25
Study 3520469 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 93
Study 3520469 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate potassium (Augmentin)
Number of subjects: 93
Study 3520469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 29520826 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing toothpaste (triclosan/copolymer/fluoride toothpaste), used three times/day
Number of subjects: 22
Study 29520826 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fluoride toothpaste), used three times/day
Number of subjects: 22
Study 27400316 — intervention group
Group type: COMPARATOR
Intervention: BNP reduction tertile 1 (<27pg/mL)
Number of subjects: 245
Study 27400316 — intervention group
Group type: COMPARATOR
Intervention: BNP reduction tertile 2 (27-334pg/mL)
Number of subjects: 245
Study 27400316 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP reduction tertile 3 (>334pg/mL)
Number of subjects: 245
Study 27400316 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cohort BNP reduction
Number of subjects: 245
Study 24756139 — intervention group
Group type: EXPERIMENTAL
Intervention: Early variations of parotid gland density (rΔρ)
Number of subjects: 46
Study 24756139 — intervention group
Group type: EXPERIMENTAL
Intervention: Early variations of parotid gland volume (rΔvol)
Number of subjects: 46
Study 24756139 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rΔρ and rΔvol
Number of subjects: 46
Study 24756139 — intervention group
Group type: EXPERIMENTAL
Intervention: Median early density rate changes
Number of subjects: 46
Study 22065088 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAAs) and associated catabolites
Number of subjects: 500
Study 22065088 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 500
Study 22065088 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent cohort validation
Number of subjects: 500
Study 19618992 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and L-carnitine
Number of subjects: 75
Study 19618992 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin monotherapy
Number of subjects: 75
Study 17502531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical trial scenarios with various factors (adverse effects, trial durations, sponsors, financial incentives, conflicts of interest)
Number of subjects: 783
Study 17502531 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived probability of harm
Number of subjects: 783
Study 17502531 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived health benefit
Number of subjects: 783
Study 17502531 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived quality of care
Number of subjects: 783
Study 17502531 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of investigator patent ownership
Number of subjects: 783
Study 17502531 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 783
Study 15204348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate pMDI 200 microg b.i.d.
Number of subjects: 40
Study 15204348 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide pMDI 200 microg b.i.d.
Number of subjects: 40
Study 15204348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11576621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing's disease
Number of subjects: 44
Study 11576621 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal tumors
Number of subjects: 44
Study 11576621 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy volunteers after ACTH stimulation
Number of subjects: 44
Study 11576621 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 44
Study 9700881 — intervention group
Group type: EXPERIMENTAL
Intervention: Urogenital chlamydiosis
Number of subjects: 38
Study 9700881 — intervention group
Group type: EXPERIMENTAL
Intervention: Furunculosis
Number of subjects: 38
Study 9700881 — intervention group
Group type: EXPERIMENTAL
Intervention: Urogenital herpes
Number of subjects: 38
Study 9700881 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 8053613 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (800 mg/d)
Number of subjects: 100
Study 8053613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2498584 — intervention group
Group type: EXPERIMENTAL
Intervention: Service A (one medical school)
Number of subjects: 119
Study 2498584 — intervention group
Group type: COMPARATOR
Intervention: Service B (another medical school)
Number of subjects: 119
Study 6135430 — intervention group
Group type: EXPERIMENTAL
Intervention: GP 55 129 (4 mg)
Number of subjects: 60
Study 6135430 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 60
Study 6135430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31440873 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated game 'Lucky Lolly Slots' played for at least 5 min each week for 24 weeks
Number of subjects: 736
Study 31440873 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated game 'Lucky Lolly Slots'
Number of subjects: 736
Study 31440873 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants trying to reduce expenditure
Number of subjects: 736
Study 31094144 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA incorporating chlorhexidine (CHX)
Number of subjects: 32
Study 31094144 — intervention group
Group type: COMPARATOR
Intervention: Control discs (without CHX)
Number of subjects: 32
Study 27936344 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of HZ/su vaccine
Number of subjects: 60
Study 27936344 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) administration of HZ/su vaccine
Number of subjects: 60
Study 25678009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oseltamivir 100 or 200 mg every 12 h for 5 days
Number of subjects: 118
Study 25678009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oseltamivir
Number of subjects: 118
Study 24378599 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab retreatment
Number of subjects: 29
Study 22012543 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium Group (10% magnesium sulphate 2 mL)
Number of subjects: 66
Study 22012543 — intervention group
Group type: COMPARATOR
Intervention: Saline Group (normal saline 2 mL)
Number of subjects: 66
Study 22012543 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium Group
Number of subjects: 66
Study 22012543 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 66
Study 20889389 — intervention group
Group type: EXPERIMENTAL
Intervention: Study Care (SC): reassurance and avoidance of passive treatments, acetaminophen, 4 weeks of lumbar chiropractic spinal manipulative therapy (CSMT), and return to work within 8 weeks
Number of subjects: 92
Study 20889389 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC): family physician-directed usual care
Number of subjects: 92
Study 18065731 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 72
Study 18065731 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 72
Study 18065731 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture after crossover from sham
Number of subjects: 72
Study 15894536 — intervention group
Group type: EXPERIMENTAL
Intervention: External swing assist (ESA) device applying forces up to 4% body weight
Number of subjects: 0
Study 15894536 — intervention group
Group type: COMPARATOR
Intervention: Normal running
Number of subjects: 0
Study 15894536 — intervention group
Group type: EXPERIMENTAL
Intervention: External swing assist (ESA) device
Number of subjects: 0
Study 12478337 — intervention group
Group type: EXPERIMENTAL
Intervention: JET therapy (carboplatin 300 mg/m² on day 1 and etoposide 60 mg/m² on days 1 to 5, repeated every 6 weeks)
Number of subjects: 28
Study 12478337 — intervention group
Group type: EXPERIMENTAL
Intervention: JET therapy
Number of subjects: 28
Study 9650682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone palmitate (liposteroid) therapy (0.25 mg/kg, administered intravenously seven times over 3 months, total dosage = 1.75 mg/kg)
Number of subjects: 10
Study 9650682 — intervention group
Group type: COMPARATOR
Intervention: ACTH therapy (0.025 mg/kg/day, administered intramuscularly for 6 weeks, total dosage = 0.625 mg/kg)
Number of subjects: 10
Study 8135428 — intervention group
Group type: EXPERIMENTAL
Intervention: 50‐mL bolus of D50W followed by a normal saline infusion at 125 mL/hr for three hours
Number of subjects: 36
Study 8135428 — intervention group
Group type: EXPERIMENTAL
Intervention: 50‐mL bolus of D50W followed by an infusion of 2/3:1/3 dextrose:saline solution at 125 mL/hr for three hours
Number of subjects: 36
Study 8135428 — intervention group
Group type: COMPARATOR
Intervention: 50‐mL normal saline bolus followed by a normal saline infusion at 125 mL/hr for three hours
Number of subjects: 36
Study 2812853 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic cream, EMLA
Number of subjects: 0
Study 2812853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 884925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol alone
Number of subjects: 6
Study 884925 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiskey
Number of subjects: 6
Study 884925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol with n-propyl, n-butyl, and isoamyl alcohols
Number of subjects: 6
Study 884925 — intervention group
Group type: COMPARATOR
Intervention: Ethanol alone, Whiskey, Ethanol with n-propyl, n-butyl, and isoamyl alcohols
Number of subjects: 6
Study 31015261 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1 trap (study A)
Number of subjects: 46
Study 31015261 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1 receptor antagonist (study B)
Number of subjects: 46
Study 31015261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (study A)
Number of subjects: 46
Study 31015261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (study B)
Number of subjects: 46
Study 27514629 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised yoga training with treatment as usual (TAU)
Number of subjects: 286
Study 27514629 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise training with treatment as usual (TAU)
Number of subjects: 286
Study 27514629 — intervention group
Group type: COMPARATOR
Intervention: Supervised yoga training (YT) or supervised physical exercise training (PE)
Number of subjects: 286
Study 25620313 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 566
Study 25620313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study 23490327 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy plus pro re nata (PRN) ranibizumab
Number of subjects: 230
Study 23490327 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 Gy plus PRN ranibizumab
Number of subjects: 230
Study 23490327 — intervention group
Group type: COMPARATOR
Intervention: Sham 16 Gy plus PRN ranibizumab
Number of subjects: 230
Study 23490327 — intervention group
Group type: COMPARATOR
Intervention: Sham 24 Gy plus PRN ranibizumab
Number of subjects: 230
Study 21652615 — intervention group
Group type: EXPERIMENTAL
Intervention: sILMA™ with sILMA™ tracheal tube
Number of subjects: 80
Study 21652615 — intervention group
Group type: COMPARATOR
Intervention: i-gel™ with Magill PVC tube
Number of subjects: 80
Study 19698859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetastarch
Number of subjects: 156
Study 19698859 — intervention group
Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 156
Study 17547798 — intervention group
Group type: EXPERIMENTAL
Intervention: Dixson 0.75 kcal/ml (TPF-DM)
Number of subjects: 76
Study 17547798 — intervention group
Group type: COMPARATOR
Intervention: Nutrition MF 0.75 kcal/ml (standard formula)
Number of subjects: 76
Study 17547798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both enteral nutrition formulas
Number of subjects: 76
Study 17547798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both enteral nutrients
Number of subjects: 76
Study 15337732 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 1 month followed by 80 mg/d thereafter
Number of subjects: 4497
Study 15337732 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months followed by 20 mg/d of simvastatin
Number of subjects: 4497
Study 15337732 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/d
Number of subjects: 4497
Study 15337732 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d
Number of subjects: 4497
Study 15337732 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin only group (40 mg/80 mg)
Number of subjects: 4497
Study 15337732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4497
Study 11351146 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation-predominant IBS
Number of subjects: 22
Study 11351146 — intervention group
Group type: COMPARATOR
Intervention: Diarrhea-predominant IBS
Number of subjects: 22
Study 11351146 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (normal bowel habits)
Number of subjects: 22
Study 11351146 — intervention group
Group type: EXPERIMENTAL
Intervention: All study groups
Number of subjects: 22
Study 11351146 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxyindoleacetic acid concentrations
Number of subjects: 22
Study 9539277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxisensor FS10 (660 + 890 nm)
Number of subjects: 112
Study 9539277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxisensor FS14 (735 + 890 nm)
Number of subjects: 112
Study 9539277 — intervention group
Group type: COMPARATOR
Intervention: Pulse oximetry
Number of subjects: 112
Study 7755005 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0
Study 3294285 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 47
Study 3294285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31199173 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 0
Study 31199173 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 0
Study 27967273 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Unilateral Multidirectional (VUMD) movements
Number of subjects: 48
Study 27967273 — intervention group
Group type: COMPARATOR
Intervention: Constant Bilateral Vertical (CBV) movement (squat)
Number of subjects: 48
Study 25809332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin 24 g powder/d (n=46)
Number of subjects: 87
Study 25809332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 87
Study 22939929 — intervention group
Group type: EXPERIMENTAL
Intervention: High height z-score trajectory
Number of subjects: 170